Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | RBP4 | P02753 | 1/20 | 0.34 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.33 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.33 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26450 | 0.93 | ALDH1A1 (0.52) | TDP1ALDH1A1TSHRCA2ENPP2 | |
| SCHEMBL30038787 | 0.93 | ALDH1A1 (0.52) | TDP1ALDH1A1TSHRCA2ENPP2 | |
| SCHEMBL3426499 | 0.87 | ALDH1A1 (0.46) | TDP1ALDH1A1TSHRCA2ENPP2 | |
| SCHEMBL28107367 | 0.79 | ENPP2 (0.71) | TDP1ALDH1A1TSHRCA2ENPP2 | |
| SCHEMBL15011081 | 0.77 | ENPP2 (0.41) | TDP1ALDH1A1TSHRCA2ENPP2 | |
| SCHEMBL1507182 | 0.76 | ALDH1A1 (0.41) | TDP1ALDH1A1TSHRCA2ENPP2 | |
| SCHEMBL3419277 | 0.76 | ENPP2 (0.43) | TDP1ALDH1A1TSHRCA2ENPP2 | |
| SCHEMBL20975383 | 0.76 | ENPP2 (0.40) | TDP1ALDH1A1TSHRCA2ENPP2 | |
| SCHEMBL6048537 | 0.76 | ENPP2 (0.40) | TDP1ALDH1A1TSHRCA2ENPP2 | |
| SCHEMBL31360869 | 0.74 | CA2 (0.48) | TDP1ALDH1A1TSHRCA2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257515-B1 | 1,4-NAPHTHOQUINONE DERIVATIVES AND THERAPEUTIC USE THEREOF | CENTRE NAT RECH SCIENT (FR) | 2017-05-17 | — | — | EP | disclosed |
| US-9090549-B2 | 1,4-naphthoquinones derivatives and therapeutic use thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2015-07-28 | — | — | US | disclosed |
| US-20110059972-A1 | 1,4-NAPHTHOQUINONES DERIVATIVES AND THERAPEUTIC USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-03-10 | — | — | US | disclosed |
| EP-2257515-A1 | 1,4-NAPHTHOQUINONE DERIVATIVES AND THERAPEUTIC USE THEREOF | Centre National de la Recherche Scientifique (FR) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009118327-A1 | 1,4-NAPHTHOQUINONE DERIVATIVES AND THERAPEUTIC USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059972-A1 | 1,4-NAPHTHOQUINONES DERIVATIVES AND THERAPEUTIC USE THEREOF | NQO1, NDUFV2, RECQL | TDP1 3196/4885ALDH1A1 539/4885TSHR 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.